Meeting
2021 ASCO Annual Meeting
Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.
Authors
Mehmet Nahit Sendur
Ankara Yıldırım Beyazıt University, Faculty of Medicine and Ankara City Hospital, Ankara, Turkey
Mehmet Nahit Sendur , Martin Reck , Delvys Rodriguez-Abreu , Keunchil Park , Dae Ho Lee , Irfan Cicin , Perran Fulden Yumuk , Francisco J Orlandi , Ticiana A. Leal , Olivier Molinier , Nopadol Soparattanapaisarn , Adrian Langleben , Raffaele Califano , Balazs Medgyasszay , Te-Chun Hsia , Gregory Alan Otterson , Lu Xu , Thomas A. Burke , Ayman Samkari , Michael J. Boyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03302234
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9038)
DOI
10.1200/JCO.2021.39.15_suppl.9038
Abstract #
9038
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.
First Author: Edward B. Garon
Poster
2023 ASCO Annual Meeting
First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4‑y clinical update and outcomes by tumor histologic subtype (THS).
First Author: David Paul Carbone
Poster
2023 ASCO Annual Meeting
ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.
First Author: Richard F. Riedel
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
First Author: Martin Reck